Nitric oxide synthesis and biological functions of nitric oxide released from ruthenium compounds by PEREIRA, A.C. et al.
www.bjournal.com.br
 Volume 44 (9) 814-965     September 2011
Braz J Med Biol Res, September  2011, Volume 44(9) 947-957
 
doi: 10.1590/S0100-879X2011007500084
Nitric oxide synthesis and biological functions of nitric oxide 
released from ruthenium compounds
A.C. Pereira, M. Paulo, A.V. Araújo, G.J. Rodrigues and L.M. Bendhack
Institutional Sponsors
The Brazilian Journal of Medical and Biological Research is partially financed by 
All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License 
Faculdade de Medicina 
de Ribeirão Preto
Campus
Ribeirão Preto
Explore High - Performance MS
Orbitrap Technology
In Proteomics & Metabolomics
analiticaweb.com.br S C I E N T I F I C
www.bjournal.com.br Braz J Med Biol Res 44(9) 2011
Brazilian Journal of Medical and Biological Research (2011) 44: 947-957
ISSN 0100-879X Review
Nitric oxide synthesis and biological 
functions of nitric oxide released from 
ruthenium compounds
A.C. Pereira1, M. Paulo1, A.V. Araújo2, G.J. Rodrigues2 
and L.M. Bendhack1
1Departamento de Física e Química, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, 
Universidade de São Paulo, Ribeirão Preto, SP, Brasil
2Departamento de Farmacologia, Faculdade de Medicina de Ribeirão Preto, 
Universidade de São Paulo, Ribeirão Preto, SP, Brasil
Abstract
During three decades, an enormous number of studies have demonstrated the critical role of nitric oxide (NO) as a second 
messenger engaged in the activation of many systems including vascular smooth muscle relaxation. The underlying cellular 
mechanisms involved in vasodilatation are essentially due to soluble guanylyl-cyclase (sGC) modulation in the cytoplasm of 
vascular smooth cells. sGC activation culminates in cyclic GMP (cGMP) production, which in turn leads to protein kinase G (PKG) 
activation. NO binds to the sGC heme moiety, thereby activating this enzyme. Activation of the NO-sGC-cGMP-PKG pathway 
entails Ca2+ signaling reduction and vasodilatation. Endothelium dysfunction leads to decreased production or bioavailability 
of endogenous NO that could contribute to vascular diseases. Nitrosyl ruthenium complexes have been studied as a new class 
of NO donors with potential therapeutic use in order to supply the NO deficiency. In this context, this article shall provide a brief 
review of the effects exerted by the NO that is enzymatically produced via endothelial NO-synthase (eNOS) activation and by 
the NO released from NO donor compounds in the vascular smooth muscle cells on both conduit and resistance arteries, as 
well as veins. In addition, the involvement of the nitrite molecule as an endogenous NO reservoir engaged in vasodilatation 
will be described.
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This review will highlight the role played by endogenous 
nitric oxide (NO) generated in the vascular endothelial cells 
via endothelial NO-synthase (eNOS) activation and by NO 
released from NO donor compounds in the modulation of 
the sGC-cGMP-PKG pathway (soluble guanylyl-cyclase, 
cyclic GMP, protein kinase G) and consequent induction of 
vasodilatation. NO production is regulated by eNOS activa-
tion in response to increased cytosolic Ca2+ concentration 
([Ca2+]c) in the endothelial cells that binds to calmodulin 
in order to activate eNOS. It has been shown that calcium 
ionophore A23187 has the ability to induce [Ca2+]c increase 
in endothelial cells, with consequent [Ca2+]c decrease in the 
vascular smooth muscle cells (1). Interestingly, these effects 
are lower in the aorta of renal hypertensive rats than in the 
aorta of normotensive rats. Endothelial dysfunction can lead 
to NO deficiency, which is found in several cardiovascular 
diseases, such as hypertension. NO donors deliver NO, 
which acts as endogenous NO in vascular smooth muscle 
cells. Therefore, these compounds are suitable for either 
mimicking the endogenously produced NO or compensating 
for an endogenous NO deficiency. NO has been used as 
the pharmacological principle of nitrovasodilators that are 
therapeutically employed to promote vasodilatation. This is 
because, by activating sGC, NO maintains the vascular tone 
that is crucial for blood flow and arterial pressure regulation 
(2). A new ruthenium-derived NO donor has been reported 
to reduce mean arterial pressure in renal hypertensive rats, 
but not in normotensive rats (3). In addition, this hypotensive 
948 A.C. Pereira et al.
www.bjournal.com.brBraz J Med Biol Res 44(9) 2011
effect was obtained at a lower dose in severely hypertensive 
rats compared to moderately hypertensive rats. On the other 
hand, the vasorelaxation elicited by ruthenium-derived NO 
donor compounds was impaired in aortic rings isolated from 
renal hypertensive rats compared to normotensive rats. It 
has been demonstrated that impaired functional K+ chan-
nel activity contributes to the deficient relaxation induced 
by the NO donor trans-[RuCl([15]aneN4)NO]2+ (15-ane) in 
the aorta of renal hypertensive rats (4). 
Continuous NO production and release play an im-
portant role in vascular homeostasis. For decades it has 
been thought that NO signaling is short-lived as a result of 
its rapid reaction with hemoglobin, which makes it difficult 
to understand how the effects of NO are conserved in the 
circulation. However, a series of studies have shown that 
NO bioactivity is maintained in blood. More recently, it has 
been suggested that NO can combine with other compounds 
that can function as stable NO carriers, thereby preserving 
its bioactivity. This could help explain how systemic events 
can occur far from the NO delivery site.
This review will summarize data available on the role 
played by the NO released from endothelial cells and the 
NO delivered by NO donors in inducing vascular relaxation 
in conduit and resistance arteries as well as veins.
Nitric oxide synthesis
NO is enzymatically generated via the action of NO-
synthase isoforms (NOS). The first isoform discovered in 
the vascular endothelium (eNOS or NOS1) is present in a 
large number of cells other than endothelial cells and is the 
most important isoform participating in vascular relaxation. 
Endothelial cells play a pivotal role in vascular tone regula-
tion through the synthesis and release of contractile and 
relaxing factors. The most important vasodilating factors 
are NO, prostacyclin (PGI2), and the endothelium-derived 
hyperpolarizing factor (EDHF). Among the mediators 
produced by endothelial cells, NO is considered to be 
the key physiological molecule involved in cardiovascular 
homeostasis. Both eNOS and neuronal NOS (nNOS or 
NOS2) are constitutive under physiological conditions. On 
the other hand, inducible NOS (iNOS or NOS3) is elicited 
by cytokines in pathophysiological conditions.
In 1980, Furchgott and Zawadzki (5) reported that rab-
bit aorta stimulated with acetylcholine was relaxed only in 
preparations with intact endothelium. In contrast, denuded 
rabbit aorta failed to relax in response to acetylcholine. The 
authors attributed relaxation to the endothelium-derived 
relaxing factor (EDRF). This was the first demonstration 
that the relaxation of isolated rabbit aorta and other blood 
vessels by acetylcholine requires the presence of endothelial 
cells (5). The authors determined that acetylcholine activates 
muscarinic M3 receptors in the endothelial cells with conse-
quent EDRF release, which causes vascular smooth muscle 
cell relaxation. In fact, these findings represented a new 
era in vascular biology and in the vasodilatation process. 
Robert Furchgott, Louis Ignarro, and Ferid Murad were 
awarded the Nobel Prize for their discovery of the signaling 
properties of NO in 1998. Thus, over the last 20 years NO 
has become one of the most investigated molecules in the 
field of vascular biology.
Some years later, it was demonstrated that NO can 
be synthesized from L-arginine by cultured porcine aortic 
endothelial cells. It was proven that NO was released from 
endothelial cells stimulated with acetylcholine, bradykinin, 
and the calcium ionophore A23187 by infusion of L-arginine 
but not by D-arginine or any other closely related structural 
analogs.
NOS oxidizes the guanidine group of the enzyme sub-
strate L-arginine, which results in NO production. NOS is 
inhibited by L-arginine analogs, and the NOS isoforms differ 
in terms of their sensitivity to these analogs. The enzymatic 
activity of NOS depends on a number of cofactors. This en-
zyme is regulated by tetrahydrobiopterin (H4B), FAD, FMN, 
and NADPH. NOS shares close homology with cytochrome 
P450 reductase including FAD, FMN, and NADPH binding. 
Arginine conversion to NO is catalyzed in two steps. In the 
first step, two-electron arginine oxidation occurs, forming 
Nω-hydroxyarginine in a hydroxylation reaction that is ac-
celerated by H4B and requires calcium and calmodulin as 
activators. In the second step hydroxyarginine conversion 
to citrulline and NO takes place. In blood vessels, acetyl-
choline and other agonists activate receptors present on 
the membrane of endothelial cells. These receptors, in turn, 
activate the phosphoinositide cycle, which raises cytosolic 
calcium concentration and consequently stimulates NOS. 
Together, all of these events account for the NO-induced 
blood vessel dilatation. However, the cytosolic eNOS 
is catalytically inactive. The active non-phosphorylated 
enzyme is localized in the plasma membrane, where it 
generates the NO that is released into the extracellular 
environment. eNOS phosphorylation regulates its activity 
and subcellular distribution. 
Recently, it has been reported that in both endothelial (6) 
and vascular smooth muscle cells (7) caveolae contribute to 
the vascular relaxation prompted by acetylcholine and NO 
donors, respectively. Caveolae are abundant in endothelial 
cells, where they regulate eNOS and NO production by 
interaction with caveolin-1, the structural caveolae protein 
(8). Caveolae disruption mimics endothelial dysfunction 
since the endothelium-induced vasodilatation mediated by 
NO becomes impaired.
Many studies have demonstrated that acute NOS 
inhibition in rats promotes hypertension, which is partially 
reversed by acute administration of L-arginine, the NOS 
substrate, but not by D-arginine. Therefore, a new model 
of persistent arterial hypertension induced by chronic 
NOS blockade with the NOS substrate analog L-NAME 
has been proposed, which functions as a non-selective 
eNOS inhibitor (9). Administration of L-NAME for 4 weeks 
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in vivo increases arterial pressure and peripheral vascular 
resistance. Chronic eNOS inhibition causes endothelial 
dysfunction. This model clearly demonstrates that deficient 
NO generation can culminate in hypertension. To some ex-
tent, reduced NO bioavailability is a therapeutic goal in the 
treatment of cardiovascular disorders. Bernátová et al. (10) 
have reported that NO deficiency may be reversed either 
by interrupting L-NAME administration or by administering 
various antihypertensive drugs.
Vascular effects of NO
The multiple actions of NO rely on the interactions 
between NO and NO derivatives. The best understood 
interaction model is NO binding to the sGC metal heme 
center, which elicits sGC activation. In this case, NO binds 
to the ferrous state of the sGC β1 subunit prosthetic group, 
thereby inducing a conformational change that leads to 
sGC activation and consequent enhancement in cGMP 
production and cGMP-dependent vascular actions. The 
NO-sGC-cGMP signaling pathway regulates vasodilatation 
among other vascular functions.
In 1977, Mittal and Murad (11) published a study on sGC 
activation in numerous tissues by nitrite ion, nitroglycerin, 
nitroprusside, or NO. Guanylyl-cyclase catalyzes cGMP 
production from GTP. These authors also showed that 
partially purified rat liver sGC accounted for superoxide ion 
formation, and they proposed that the resulting superoxide 
ion and H2O2 furnished hydroxyl radicals, which can ac-
tivate guanylyl-cyclase. This activation mechanism could 
explain the altered guanylyl-cyclase activity and cGMP 
production in tissues with oxidizing and reducing agents. 
This mechanism also permits physiological regulation of 
cGMP production when there is altered redox or free radi-
cal formation in tissues in response to hormones or other 
physiological substances.
Endothelial NO generation results in local formation 
of storage NO forms. The existence of stored NO forms 
was first examined by light-induced vasorelaxation. In our 
laboratory, it has been shown that photo induction of the 
complex 15-ane elicits complete aorta relaxation, which is 
due to NO delivery to the extracellular medium (12).
Ruthenium compounds as vasodilating 
drugs 
NO is a stable free molecule that has been recognized 
as an effective compound in diverse physiological and 
pathological processes. Because some diseases have been 
associated with NO deficiency, great interest in exogenous 
NO donors that can deliver NO to specific targets under 
stimulation has arisen. The majority of NO donors syn-
thesized to date bear a nitroso functional group within the 
molecule. In this context, ruthenium-based metal nitrosyls 
are perhaps among the most frequently studied complexes 
for NO delivery. 
Nitrovasodilators induce vascular relaxation by NO 
generation. Some nitrovasodilators have been employed in 
the clinical setting, including organic nitrites or nitrates (e.g., 
amyl nitrite and nitroglycerin, respectively) and inorganic 
sodium nitroprusside (SNP). The organic nitrovasodilators 
are primarily used for the management of angina pectoris, 
whereas SNP is used for the immediate management 
of hypertensive emergencies. However, both classes of 
compounds exhibit undesirable side effects. Continuous 
exposure to nitroglycerin leads to the development of nitrate 
tolerance. High doses, prolonged use, or simply the use of 
SNP in patients with compromised hepatic function is as-
sociated with accumulation of cyanide and its metabolite 
thiocyanide. In this respect, new nitrosyl ruthenium com-
pounds with improved pharmacological properties and that 
can act as NO donors have been developed as alternative 
vasodilators. Figure 1 shows the structure of the organic 
nitrates (nitroglycerin), inorganic nitrates (sodium nitroprus-
side) and ruthenium compounds as NO donors.
The ability of ruthenium to mimic the iron binding 
mode to many biological molecules, like serum transferrin 
and albumin, is believed to contribute to its generally low 
toxicity (13).
Countless nitrosyl ruthenium compounds have been in-
vestigated as NO donors, and it has been demonstrated that 
they can release NO under reduction by biological reducing 
agents or light (12-17). These ruthenium complexes were 
able to elicit aortic vasodilatation in physiological conditions 
(4,15,16). The mechanism of vasodilatation promoted by 
ruthenium compounds has been attributed to NO release 
(18) and its action on smooth muscle cells, including sGC 
(16,19) and K+ channel (4,16,19) activation, which in 
turn prompt decreased cytosolic calcium concentration 
(7,18,20,21) and finally aorta relaxation. 
The potency of some ruthenium compounds with regard 
to vascular relaxation induction is lower than that of SNP 
(14,21). The time elapsed until some ruthenium complexes 
induce maximum relaxation is longer compared to SNP, 
which indicates that ruthenium compounds provide slow NO 
release (14). Figure 2 demonstrates how the compounds 
nitroglycerin, SNP and a ruthenium complex release NO. 
In vivo studies have demonstrated a hypotensive effect for 
some ruthenium complexes in different hypertensive animal 
models (3,22), and a long-lasting hypotensive event was 
observed (3). This characteristic allows maintenance of 
low arterial pressure levels for long periods of time when 
ruthenium complexes are used, which is not possible in 
the case of SNP. 
A couple of ruthenium compounds have been developed 
as NO scavengers (23). For example, [Ru(Hedta)(H2O)] 
(23) and trans-[Ru-(Cl)(H2O)(cyclam)], in which NO can 
coordinate with ruthenium and replace the H2O molecule, 
have the ability to scavenge NO. The hypotensive effect 
induced by trans-[Ru-(Cl)(NO)(cyclam)](PF6)3 was abol-
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Figure 1. Structures of ruthenium complexes, organic nitrates and inorganic nitrates.
Figure 2. Nitric oxide (NO) release from ruthenium complexes, inorganic nitrate (sodium nitroprusside, 
SNP), and organic nitrate glyceryl trinitrate, GTN). L = ligand; P = product.
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ished in the presence of the NO scavenger trans-[Ru-(Cl)
(H2O)(cyclam)]. The NO scavenging action displayed by the 
ruthenium complex could be explored in some pathological 
conditions, including septic shock, when there is high NO 
production by iNOS (24). Septic shock reflects the end of 
a continuous progressive pathophysiological deterioration 
culminating in hypotension and hypoperfusion. Hypoperfu-
sion causes organ dysfunction, which leads to death. This 
pathological condition could be reversed by a ruthenium 
compound with NO scavenging action. 
Hypertension and endothelial dysfunction 
Resistance vessels are those that concentrate most 
of the pressure drop that must occur between large con-
duit arteries and capillaries. It has been underscored that 
their exact anatomical location is hard to define precisely 
(25), but they are commonly believed to encompass small 
arteries and arterioles, with diameters ranging from 15 to 
300 µm. 
Although all blood vessels must contribute to vascular 
bed resistance to some extent, in general it is the smaller 
arterial resistance vessels that present the greatest resis-
tance and that are involved the most in regulating blood 
flow and capillary pressure.
In many pathological situations, in particular hyperten-
sion, resistance arteries are considered to play an impor-
tant role in the etiology of the disease, and some authors 
have even suggested that development of resistance 
artery abnormalities could be the primary event in such 
processes.
Hypertension is usually associated with impaired en-
dothelium-dependent vasorelaxation in response to several 
stimuli. Acetylcholine-induced vasorelaxation is blunted in 
conduit vessels from genetic and experimental hypertensive 
rodent models such as spontaneously hypertensive (SHR), 
deoxycorticosterone acetate (DOCA) salt-induced hyperten-
sive, renovascular hypertensive, and angiotensin II-infused 
(ANG) hypertensive rats. However, both unchanged and 
impaired acetylcholine-induced vasorelaxation have been 
observed to occur in small mesenteric arteries from hyper-
tensive rats in various experimental hypertension models 
such as DOCA salt, SHR, and ANG rats. Therefore, NO 
bioavailability in resistance arteries may be different from 
that observed in conduit vessels (26).
Many studies have reported on the similar acetyl-
choline-induced relaxation taking place in normotensive 
and hypertensive animals (27). The relaxation induced 
by acetylcholine was shown to be unchanged in small 
mesenteric arteries from renovascular (28) and DOCA-salt 
hypertensive rats (29). 
In contrast, Liu et al. (27) have observed that acetylcho-
line-induced relaxation was diminished in small mesenteric 
arteries from SHR compared to normotensive rats. Kang et 
al. (26) observed that the acetylcholine-induced relaxation 
is less potent in small mesenteric arteries from rats made 
hypertensive by angiotensin II infusion.
Acetylcholine-induced relaxation is lower in basilar ar-
teries, which are also resistance vessels, from SHR when 
compared to WKY (30). 
As in the case of acetylcholine, there are some investi-
gations showing that the NO donor-induced relaxation may 
remain unchanged or become impaired during hypertension. 
The relaxation prompted by the NO donor SNP has been 
demonstrated to continue unchanged in small mesenteric 
arteries from genetically hypertensive, SHR, and ANG rats 
(26,27). Briones et al. (31) have reported that endothelium-
dependent relaxations in response to bradykinin or sodium 
nitroprusside were similar in middle cerebral arteries from 
normotensive rats and SHR, while the endothelium-indepen-
dent response to SNP was smaller in SHR middle cerebral 
arteries. Nevertheless, the relaxation induced by another 
NO donor, namely S-nitroso-N-acetylpenicillamine (SNAP), 
is less pronounced in coronary arteries from renovascular 
hypertensive rats compared to normotensive rats, although 
the measured NO was similar.
Concerning sGC activation, the relaxation promoted by 
the NO donor diethylamine-NONOate (DEA-NONOate) in 
mesenteric resistance arteries is less potent in the presence 
of ODQ, a selective inhibitor of the sGC isoform. ODQ also 
induced marked inhibition of relaxation responses to SNP 
in rat basilar artery. 
The mechanisms involved in the NO-induced relaxation 
by resistance vessels are similar to the ones implicated in 
conduit vessels and seem to entail mainly the sGC/cGMP/
PKG pathway and K+ channel activation. The latter may 
also be implied in NO-induced relaxation in resistance 
arteries. The relaxation elicited by DEA-NONOate was 
inhibited by the K+ channel blocker 4-aminopyridine (4-AP) 
in rat basilar arteries. Moreover, a relatively low concentra-
tion of 4-AP, which is thought to be selective for inhibition 
of voltage-dependent K+ channels (32) prompted basilar 
artery constriction, suggesting that under normal conditions 
activity of voltage-dependent K+ channels may influence 
the basal tone of cerebral arteries in vivo. However, a role 
for ATP-sensitive (KATP) or calcium-sensitive (KCa) K+ 
channels could not be observed.
The participation of K+ channels (KIR) has also been 
evaluated. Schubert et al. (33) observed that the relaxation 
induced by SNP in rat tail small arteries was less potent in the 
presence of barium, a selective KIR blocker. In addition, SNP 
increased the amplitude of the KIR current, and this effect 
was almost abolished in the presence of barium, indicating 
that KIR participates in the SNP-induced relaxation.
The relaxation elicited by DEA-NONOate in mesenteric 
resistance arteries was less potent in the presence of cha-
rybdotoxin, suggesting involvement of calcium-activated K+ 
channels in this response (33).
Moreover, it has been observed that high extracellular 
K+ concentration partly inhibited the relaxant effects of the 
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NO donors DEA-NONOate and 3-morpholino-sydnonimine 
in rat basilar artery. While single applications of the K+ 
channel inhibitors tetraethyl-ammonium, glibenclamide, 
4-AP, or BaCl2 did not affect the responses to DEA/NO, a 
combination of these inhibitors reduced the effects of DEA-
NONOate. These data indicate that the relaxant effects of 
NO donors are partly mediated via K+ channel activation, 
and that different K+ channel types seem to be involved 
that function in a redundant manner and compensate for 
each other.
Some studies have reported alterations in the cellular 
mechanisms implicated in the relaxation taking place 
during hypertension. According to Kang et al. (26), K+ 
channel activation is impaired in small mesenteric arter-
ies from ANG hypertensive rats, which is consistent with 
previous reports on SHR small mesenteric arteries. More-
over, Kang et al. (26) have shown that basal as well as 
acetylcholine-stimulated cGMP production is diminished 
in small mesenteric arteries from ANG hypertensive rats 
compared to normotensive rats. As demonstrated by Liu 
et al. (27), acetylcholine induced a significant increase in 
intracellular cGMP content from baseline in preparations 
from both genetically hypertensive New Zealand rats and 
normotensive rats. The extent of this increase was similar 
in these two rat strains. However, acetylcholine failed to 
increase the cGMP content in SHR arteries.
Veins and vascular tone control: role of NO
Compared to arteries, less attention has been given to 
the role of veins in vascular tone regulation. Nevertheless, 
two thirds of the circulating blood volume is in the veins at any 
given time. Veins and venules serve as a readily adjustable 
volume reservoir that can shift blood to or from the heart 
by both passive and active processes. The venous system 
contains about 70% of the blood volume, with approximately 
three-quarters of this volume being found within small veins 
and venules. The venous section of the cardiovascular 
system can be looked upon as a voluminous blood reser-
voir designed to preserve a proper inflow of blood into the 
heart during various cardiovascular adjustments. Venules 
and small veins are undoubtedly the most important blood 
reservoir within the circulatory system (34). 
In contrast to arteries, veins have thinner walls, greater 
compliance, and valves to prevent retrograde flow. The 
major vein components are smooth muscle and the fibrous 
proteins collagen and elastin. The muscle fibers are respon-
sible for contraction, while the collagen and elastin fibers 
account for the vessel’s passive or viscoelastic properties. 
Veins have more collagen, but less elastin and smooth 
muscle compared to arteries. The venous system is the 
primary capacitance region in the body, and therefore altera-
tion of its capacity greatly affects venous return and cardiac 
output. The venous tone or venomotor tone should not be 
confused with venous return. The body’s venomotor tone 
is determined by venous compliance, venous resistance, 
and blood volume (35). Venous return, on the other hand, 
is controlled by cardiac as well as vascular factors, which 
include arterial and venous resistance, arterial and venous 
compliance, cardiac contractility, heart rate, and blood 
volume (35). Hence, the body venous tone is an important 
determinant of cardiac output. There are few studies on the 
venous system despite its importance in carbon monoxide 
and mean arterial pressure control. Increased venomotor 
tone and reduced compliance in peripheral veins shift 
blood to the small arteries, thereby elevating arterial blood 
pressure. Hypertensive humans and experimental animals 
have decreased venous capacitance because of reduced 
compliance (36). 
The importance of the endothelium and of NO for 
the arterial circulation is well recognized. In the arterial 
circulation, endothelium-derived NO release is stimulated 
by shear stress and agonists such as acetylcholine, car-
bachol, and bradykinin (37). The role played by NO in 
venous tone regulation is less clear. Several studies have 
suggested that NO activity varies between different venous 
preparations. Vedernikov et al. (38) demonstrated marked 
endothelium-dependent relaxation in jugular, femoral, and 
mesenteric veins. However, such activity was not observed 
in the saphenous, portal, or inferior cava veins, despite 
preservation of endothelium-independent relaxation in 
response to SNP. 
Recent investigations have indicated that basal NO 
activity may contribute to the resting venous tone. In a study 
involving awake rats, L-NG-monomethyl arginine (L-NMMA) 
caused a dose-dependent rise in the mean circulatory filling 
pressure, which was reversed by L-arginine administration 
(39). The endothelium regulates arterial and venous tone in 
a similar way. In the bovine pulmonary vascular bed (40) and 
in ovine pulmonary vessels, NO preferentially regulates the 
venous tone. Bäck et al. (41) have shown that acetylcholine 
elicits endothelium-dependent relaxation that is greater in 
porcine pulmonary veins compared to arteries. 
The NO released by arteries and veins enhances cGMP 
levels via sGC stimulation. It has been proven that in both 
porcine pulmonary arteries and veins the basal tension 
increased after the addition of the NOS inhibitor L-NOARG, 
whereas indomethacin, which inhibits prostanoid production 
by cyclooxygenase alone, did not modify the basal tone. 
These findings suggest that in the porcine pulmonary vascu-
lature, NO, but not the cyclooxygenase pathway, regulates 
the basal tone. The differences in NO regulation between 
porcine pulmonary arteries and veins are due to the fact that 
larger NO amounts are released from the veins compared 
to arteries, rather than to a difference in sensitivity to either 
NO or cGMP between the two preparations. This obser-
vation is supported by a previous biochemical study that 
demonstrated both a greater basal NO release and a larger 
quantity of constitutive NO protein in porcine pulmonary 
veins compared to arteries. In addition, a lesser degree of 
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cGMP metabolism was detected in veins compared to arter-
ies (42). Evidence that SNP-induced relaxation is similar 
in arteries and veins was also provided. Interestingly, the 
biochemical differences in phosphodiesterase activity may 
not affect the functional responses.
Effect of NO donors on veins
Vasoactive drugs that interfere with the body’s venous 
tone have profound effects on hemodynamics and blood 
pressure. This is exemplified by the occurrence of postural 
hypotension following administration of drugs that cause 
venodilation either directly (e.g., nitrovasodilators) or indi-
rectly by interfering with the activities of the sympathetic 
nervous system (e.g., α-adrenoceptor antagonists and 
ganglionic blockers). NO donors are pharmacologically 
active substances that release NO in vivo or in vitro. The 
classical NO donors are nitroglycerin and SNP, which exert 
an important therapeutic effect on the treatment of many 
cardiovascular disorders such as angina pectoris and 
hypertension. A major clinical benefit of NO donors is their 
venodilating effect, which culminates in reduced venous 
return, cardiac preload, high blood pressure, and decreased 
myocardial oxygen demand. Currently, available NO donors 
employed in the clinical setting are more potent vein dilators 
compared to the resistance vasculature, and this vascular 
profile contributes to their efficacy in the treatment of angina 
and heart failure (43). It has been hypothesized that the 
increased sensitivity of veins to NO donors compared to 
resistance arteries is related to the degree of basal endog-
enous NO-mediated dilatation in these vessels. 
Contrary to resistance vessels, veins exhibit minimal 
basal NO, and this might lead to increased venous vascular 
smooth muscle sensitivity to NO donors (44). Secondary to 
the up-regulation of the NO transduction pathway in vascular 
smooth muscle, NO stimulates sGC present in vascular 
smooth muscle to synthesize cGMP. In the presence of 
endogenously synthesized NO, there is evidence that sGC 
is down-regulated, resulting in reduced responsiveness to 
NO donors (45).
Nitrite, nitrate and nitric oxide  
 
The half-life of NO in blood is thought to be very short, 
mainly due to its rapid inactivation after scavenging reac-
tions involving hemoglobin, myoglobin, and other radicals. 
Therefore, NO has been regarded as an autocrine and 
paracrine signaling molecule with effects in the close vi-
cinity of its production site only. More recently, it has been 
suggested that NO can combine with other compounds 
that can function as stable NO carriers, thereby conserv-
ing its bioactivity. A major pathway for NO inactivation is 
its oxidation to nitrite and nitrate, which can be considered 
endocrine molecules. 
The nitrite anion (NO2-) represents an interesting 
constituent of the nitrogen oxides (NOx) family. Together 
with nitrate (NO3-), NO2- is predominantly known as an 
undesirable residue in food with carcinogenic effects (46) 
or as an endogenous NO oxidation metabolite under normal 
physiological conditions (47). NO2- has long been believed 
to be relatively inert at the low micromolar levels that are 
normally found in vivo. In early in vitro studies, as reported 
by Furchgott and Bhadrakom (48), high NO2- concentra-
tions (≈100 µM) were typically used to induce aortic ring 
relaxation or to activate purified sGC, the enzyme that 
catalyzes the conversion of guanosine triphosphate (GTP) 
to cGMP and that mediates NO vasorelaxation (49). The 
high NO2- concentrations required for vasodilatation of 
aortic ring bioassay systems, at room oxygen and neutral 
pH, has led to the dismissal of NO2- as a physiologically 
vasoactive mediator.
Nevertheless, it has been reported that NO2- can be a 
source of NO in ischemic tissues, where it is reduced back 
to NO. Research performed over the years by several labo-
ratories has shown that different pathways exist to recycle 
this anion back into bioactive NO in blood and tissues, and 
that NO2- is a potential supplementary NO source that offers 
therapeutic benefit (50). More recently, it has become clear 
that NO2- has a complex in vivo chemistry that is associated 
with NO signaling pathways, particularly with regard to the 
control of vasodilatation (51).
Until recently, it was generally accepted that the only 
pathway of NO release in vivo was the oxygen-dependent 
conversion of arginine to citrulline and NO via NOS. 
However, NO3- and NO2- can be viewed as storage pools 
supporting NO signaling during metabolic stress, with their 
bioactivation involving both enzymatic and non-enzymatic 
reactions in blood and tissues. NO3- bioactivation entails 
an initial reduction to NO2- by symbiotic bacteria in the oral 
cavity (52). The commensal bacteria use NO3- as an electron 
acceptor alternative to oxygen during respiration, which 
culminates in NO3- reduction to NO2- by the action of nitrate 
reductases. In 2004, Lundberg and Govoni (53) reported 
that NO3- is a substrate for systemic NO2- generation. They 
tested whether inorganic NO3- ingestion would affect the 
levels of salivary and systemic NO2- and S-nitrosothiols, 
both considered to be circulating storage pools for NO. 
Patients presented a 4-fold increase in plasma NO2- after 
inorganic NO3- ingestion (53). In the same way, another 
study demonstrated that ingestion of beet juice, which 
is rich in NO2-/NO3-, by healthy volunteers boosted the 
plasma levels of NO2- and NO3-. The study further showed 
that bacterial-mediated conversion of NO3- to NO2- on the 
tongue could significantly elevate NO2- levels in plasma, thus 
accounting for cardiovascular events such as a reduction 
of blood pressure to ≈10 mmHg, which were abated when 
microbes were eliminated by spitting (54). Salivary-derived 
NO2- is non-enzymatically reduced in the acidic gastric 
environment, to form NO and other nitrogen oxides. NO2- 
reduction to NO is greatly enhanced by reducing compounds 
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such as vitamin C and polyphenols. There are numerous 
pathways for further reduction of this NO2- to NO. These 
results challenge the dogma that NO2- is biologically inert 
and instead suggest that a complete reverse pathway for 
NO generation from NO3- exists. 
Several mechanisms for NO2- reduction to NO have 
been identified including: 1) Nonenzymatic disproportion-
ation at low pH. NO2- reduction to NO is favored by low 
pH and a reducing milieu (55). In 1999, Zweier et al. (55) 
demonstrated that enzyme-independent NO formation 
occurs in biological systems under acidic conditions and 
is further increased in the presence of a highly reduced 
metabolic state. The substrate source of this NO is NO2- 
rather than the NOS substrate L-arginine. Under hypoxic 
conditions, this NO accumulates in tissues and binds to a 
variety of cellular heme proteins. In important disease states, 
such as ischemia or shock, where acidosis and marked 
hypoxia take place, this pathway becomes the major NO 
source and the magnitude of NO generation can be much 
greater than that which would be found at normal NOS 
tissue concentrations. 
2) Reduction of circulating NO2- to NO during tissue 
hypoxia. Many mechanisms for the NO2--mediated vasodi-
latation during hypoxia have been proposed over the past 
years. These are essentially based on nonenzymatic (55) 
or enzymatic NO2- reduction to NO (53). Zweier et al. (55) 
have shown the occurrence of systemic NO generation from 
NO2-. They found that N15-labeled NO2- was reduced to NO in 
ischemic rat hearts, and that NO production was not blocked 
by NOS inhibitors. During global ischemia in the heart, pH fell 
to ≈5.5, and under these conditions, NO2- reduction to NO 
was greatly accelerated. A key point of NO2- pharmacology 
is that its vasodilating properties are notably enhanced during 
hypoxia compared to normoxia. Previous studies have sug-
gested that the NO2- hypoxic vasodilatation is independent 
of eNOS, but depends on sGC, supporting the hypothesis 
that NO mediates these effects. The authors (55) proved 
that nitrite vasodilatation does not seem to depend on the 
activity of previously identified NO2- reductases, such as 
xanthine oxidase and the mitochondrial bc1 complex, which 
may generate NO from NO2-. 
3) Enzymatic conversion. A number of publications now 
state that oxidoreductase enzymes are able to convert 
significant amounts of NO2- to NO, in particular xanthine oxi-
dase and aldehyde oxidase (56). Xanthine oxidoreductase 
is known to reduce molecular oxygen to superoxide (O2-), 
but at low oxygen tensions and pH values this enzyme 
can also reduce NO2- to NO at the molybdenum site of the 
enzyme. Li et al. (56) have shown that administration of the 
xanthine oxidase inhibitor oxypurinol or of the aldehyde 
oxidase inhibitor raloxifene considerably diminished NO 
generation from NO2- in the heart and liver. NO formation 
rates were dramatically increased with decreasing pH and 
lower oxygen tension. 
4) Reduction process. It is possible that NO2--derived 
NO acts not only through sGC, but is also generated by 
sGC in a reductive process (57). It has been reported that 
both vasorelaxation and NO generation were abolished by 
an sGC inhibitor (ODQ, 10 µM). Therefore, Alzawahra et al. 
(57) concluded that the dose-dependent vasodilating effects 
of exogenous inorganic NO2- are due to NO formation by 
a process mediated by sGC and/or other heme enzymes 
under aerobic conditions. Reduction by deoxyhemoglobin 
has also been reported. During NO2- infusion into the hu-
man forearm circulation, the observed vasodilating effects 
are associated with eNO formation in blood, as measured 
by the rate of iron-nitrosylated hemoglobin (NO bound to 
the heme of hemoglobin) formation during artery to vein 
transit. The NO formation rate increases as the hemoglobin 
oxygen saturation falls, suggesting a hypoxia-regulated 
mechanism for NO2- bioactivation (50). These same authors 
published the first report demonstrating vasodilatation in 
humans prompted by NO2- infusions at near physiological 
levels. Experiments have also pointed to the novel role 
of deoxyhemoglobin as a functional NO2- reductase that 
contributes to vasodilatation. This complex was considered 
to be the largest intravascular storage pool for NO, and it 
was deduced that NO2- bioactivation to NO could promote 
vasodilatation in regions with oxygen debt in the human 
circulation. Myoglobin has high affinity for oxygen and a low 
heme redox potential, which aids rapid NO2- reduction to 
NO when it is deoxygenated. In fact, deoxymyoglobin will 
reduce NO2- to NO thirty times faster than hemoglobin.
All in all, the findings of the several studies mentioned 
here reinforce the view that NO2- is not simply an undesired 
residue in food but that it might have a crucial role in main-
taining healthy, particularly in hypoxia. The NO3--NO2--NO 
pathway is very important when oxygen availability is re-
duced and NOS activity is decreased, when NO2- reduction 
to NO becomes more evident. It is possible that increasing 
knowledge about NO2--derived NO can lead to the devel-
opment of new drugs for use in cardiovascular medicine. 
NO2--based pharmaceuticals that selectively deliver NO to 
ischemic areas only are indeed an interesting alternative 
approach.
Nitric oxide bioconversion
NO can exist in a variety of molecular forms; for instance, 
as free radical (NO0) and nitrosyl (NO-) or nitrosonium ions 
(NO+), with the form depending on the NO source. Hence, 
the NO released from NO donors can differ from the NO 
produced in the endothelial cells. This could explain the 
differences in potency and efficacy of the known NO donors 
when inducing vasodilatation. NO donors are pharmaco-
logically active substances that release NO in vivo or in 
vitro. NO delivery can occur through many kinds of stimuli, 
depending on the NO donor structure. 
In the case of the NO donor SNP, an NO molecule is 
coordinated to the iron metal, forming a square bipyramidal 
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complex with five cyanide anions (CN-). It has been dem-
onstrated that SNP does not release NO spontaneously, 
but NO release from SNP happens when SNP is irradiated 
with visible light at rates linearly proportional to the light 
intensity. NO production by SNP also requires enzymatic 
metabolism. These enzymes are present in the vascular 
tissue, and therefore the use of reducing agents is another 
way to achieve NO release from SNP (58). NO generation 
is preceded by CN- release, which is toxic to cells and is 
thus an important limitation of the pharmacological use 
of SNP. 
Other NO donors, namely nitrosyl ruthenium complexes, 
investigated in our laboratory also provide different means 
of NO release. The NO donor trans-[RuCl([15]aneN4)NO]2+ 
requires chemical reduction to induce relaxation. This 
mechanism was demonstrated by Bonaventura et al. (14) 
when the concentration-response curves for trans-[RuCl([15]
aneN4)NO]2+ were evaluated in the absence of reducing 
agent. Unlike the last complex, the nitrosilo-terpyridine-phe-
nylene-diamine ruthenium (II) ion complex ([Ru(terpy)(bdq)
NO+]3+) has its vascular relaxation effect accelerated in the 
presence of light (15), but it does not need to be reduced to 
elicit vasorelaxation. cis-[RuCl(bpy)2(NO)](PF6) (RUNOCL) 
is another nitro ruthenium NO complex that releases NO 
upon activation by light irradiation. The RUNOCL profile can 
be a helpful tool in therapies dealing with light activation 
process, such as photodynamic therapy (59).
Today, there are at least four organic nitrates of thera-
peutic relevance in the treatment of angina and myocardial 
infarction, more specifically nitroglycerin, pentaerythrityl tet-
ranitrate, isosorbide dinitrate, and isosorbide-5-mononitrate. 
Nitroglycerine has been renamed glyceryl trinitrate (GTN) 
to avoid the anxiety associated with ingestion of a potential 
explosive, and has been continuously used for the treatment 
of angina since 1878. GTN has also been applied to control 
hypotension during cardiac surgery and in congestive heart 
failure. Only in 2002 did Chen et al. (60) show that mito-
chondrial aldehyde dehydrogenase (ALDH-2) significantly 
metabolizes nitroglycerin in vitro and in vivo, and that inhibi-
tion of this enzyme markedly decreases the vasodilating 
potency of GTN. The NO2- generated by ALDH-2 from its 
parent nitroglycerin within the mitochondria is then further 
metabolized by reduction to NO and/or by conversion to 
S-nitrosothiol, to promote NO-based bioactivities.
In contrast to organic nitrates and nitrate-like agents, 
direct NO donors release NO spontaneously, without the 
need for metabolism and biotransformation. The NO gas 
has been useful in the treatment of multiple respiratory 
disorders and is the first vasodilator to produce selective 
pulmonary vasodilatation. The compounds called NONO-
ates have NO bound to a nucleophile, with up to 40% NO 
content by weight. They are direct NO donors since they 
release NO at physiological pH and require no metabolism or 
redox activation. S-nitrosothiols are endogenous, naturally 
occurring moieties on proteins that are generated when 
the thiol of cysteine reacts with NO in the presence of an 
electron acceptor, to form an S-NO bond. S-nitrosothiols 
act as NO reservoirs, and their degradation, which may 
occur through a number of enzymatic systems, results in 
spontaneous NO release. 
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